Product Description
Mechanisms of Action: HDAC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Helsinn Healthcare
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Myeloid Leukemia
Phase 2: Myelodysplastic Syndrome|Preleukemia|Acute Myeloid Leukemia|Sarcoma|Myelofibrosis|Prostate Cancer|Myeloproliferative Disorders|Polycythemia Vera|Thrombocythemia, Essential
Phase 1: Preleukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Leukemia|Tobacco Use Disorder|Oncology Solid Tumor Unspecified|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
---|---|---|---|---|---|---|---|
2016-004724-34 | N/A |
Terminated |
Acute Myeloid Leukemia |
2020-07-02 |
2025-06-17 |
Treatments |
|
2006-7041-83/hah | N/A |
Not yet recruiting |
Suicidality |
2019-01-31 |
|||
PRO 33922 | P1 |
Completed |
Acute Myeloid Leukemia |
2021-05-05 |
2022-07-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
PRAN-17-17 | P1 |
Completed |
Healthy Volunteers |
2018-02-28 |
59% |
2019-08-10 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Trial Status |
MEI-007 | P1 |
Completed |
Tobacco Use Disorder |
2014-06-01 |
2024-11-27 |
Primary Endpoints |
|
HVFE | P1 |
Completed |
Tobacco Use Disorder |
2014-03-01 |
2019-03-20 |
Treatments |
|
I203 | P1 |
Completed |
Leukemia |
2012-04-12 |
2023-08-05 |
Primary Endpoints|Start Date|Treatments |
|
SB939-2006-001 | P1 |
Completed |
Myelodysplastic Syndrome|Preleukemia |
2012-03-01 |
2019-03-18 |
Treatments |
|
I188 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-04-22 |
2023-08-05 |
Primary Endpoints|Start Date|Treatments |
|
MEI-011 | P2 |
Terminated |
Preleukemia|Myelodysplastic Syndrome |
2020-12-01 |
38% |
2022-03-03 |
|
NCI-2015-00002 | P2 |
Completed |
Myelofibrosis|Myeloproliferative Disorders |
2018-06-01 |
36% |
2019-03-20 |
Treatments |
MEI-004 | P2 |
Completed |
Acute Myeloid Leukemia |
2016-11-08 |
2021-02-11 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
MEI-003 | P2 |
Completed |
Myelodysplastic Syndrome|Preleukemia |
2015-11-01 |
2019-03-19 |
Treatments |
|
MEI-005 | P2 |
Completed |
Preleukemia|Myelodysplastic Syndrome |
2015-05-01 |
2019-03-20 |
Treatments |
|
I195 | P2 |
Completed |
Prostate Cancer |
2015-01-05 |
2023-08-05 |
Primary Endpoints|Start Date|Treatments |
|
IND200 | P2 |
Completed |
Sarcoma |
2013-01-21 |
2023-08-05 |
Primary Endpoints|Start Date|Treatments |
|
NCT01200498 | P2 |
Completed |
Thrombocythemia, Essential|Myelofibrosis|Polycythemia Vera|Myeloproliferative Disorders |
2012-11-01 |
2019-03-19 |
Treatments |
|
PRAN-16-52 | P3 |
Terminated |
Acute Myeloid Leukemia |
2020-08-20 |
43% |
2024-06-26 |
Primary Endpoints|Treatments |
CTR20191971 | P3 |
Terminated |
Acute Myeloid Leukemia |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |